| HOME >> BIOLOGY >> TECHNOLOGY |
CALGARY, March 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that abstracts covering research with reovirus (REOLYSIN(R)) are available on the American Association for Cancer Research (AACR) website at www.aacr.org, and on the Oncolytics website at www.oncolyticsbiotech.com. The research is scheduled to be delivered at the 100th AACR Annual Meeting in Denver, Colorado, April 18-22, 2009.
The first abstract, entitled "Reovirus Infection in Combination with Chemotherapy Improves the Efficacy of Treatment in Primary Cultures of Patient Derived Epithelial Ovarian Cancer" covers preclinical work using reovirus in combination with cisplatin, paclitaxel and gemcitabine. The combination of reovirus with chemotherapy induced an additive effect in most cases, however a clear synergistic response was seen at certain dose combinations in more than 30 per cent of the samples treated with reovirus and paclitaxel.
The investigators concluded that the data supports a significant synergistic effect of reovirus and paclitaxel. A poster presentation is scheduled to be delivered by Dr. Geoff Hall and his research group from St. James's Hospital in Leeds, U.K., on Sunday, April 19, 2009.
The second abstract, entitled "Clinical Evidence of Reovirus Oncolysis in Human Prostate Cancer" reports on early clinical work using reovirus in a small cohort of prostate cancer patients prior to prostatectomy. Six prostate cancer patients with cancer confined to the prostate gland received a single injection of REOLYSIN(R), followed by prostatectomy several weeks later. Intralesional reovirus injections resulted in minimal side effects, and evidence of anti-tumour activity. There was no evidence of viral spread to adjacent
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2009 PR Newswire. All rights reserved |